Cambridge Cognition wins £1.3 million contract as the cognitive assessment partner for a schizophrenia trial

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has won a £1.3 million contract as the cognitive assessment partner for a schizophrenia trial. Revenue from the contract is expected to be booked over the next three years. This is the fourth schizophrenia trial Cambridge Cognition has secured with this pharmaceutical client in seven months. The first three were announced by the Company on 1 September 2020 in a £2 million contract.

Cognitive impairment is a core feature of schizophrenia, with deficits frequently observed in memory, attention and executive functions. Impressed by the high degree of sensitivity CANTABTM cognitive assessments demonstrate in measuring these distinct processes and the quality of service the Company delivers, Cambridge Cognition has been named as the cognitive assessment provider for the fourth trial in the series.  

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

“Schizophrenia affects more than 20 million people worldwide and we are pleased to be strengthening our relationship with a company that recognises the importance of sensitive and accurate cognitive assessment in developing effective therapeutics for the disorder. This quick succession of unusually large contracts with the same pharmaceutical company is a testament to the excellent customer experience and high-quality products Cambridge Cognition delivers.”  

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Cambridge Cognition Holdings

More articles like this

Cambridge Cognition Holdings

Cambridge Cognition wins eCOA contract worth over £500,000

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has won a contract worth over £500,000 to provide electronic clinical outcome assessments to support a major

Cambridge Cognition Holdings

Cambridge Cognition growth in revenue of 50% to £4.5 million

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced a positive trading update for the six months ended 30 June 2021. The Company enjoyed a strong performance in the

Cambridge Cognition Holdings

Cambridge Cognition completes spin-out of Monument Therapeutics

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced the completion of the spin-out of Monument Therapeutics Limited, a drug development company applying digital phenotyping to central nervous